Fast Censure for Glueck

WASHINGTON—The recent censure of Charles J. Glueck for misreporting his studies of children on low-cholesterol diets illustrates the biomedical community’s increasing concern about scientific misconduct, according to NIH Deputy Director William Raub. Glueck, who has received several NIH grants, was formally censured by the agency last month. It has recommended that Glueck be barred from receiving any federal funds for two years, and banned from serving on any government advisory g

Written byCharles Marwick
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WASHINGTON—The recent censure of Charles J. Glueck for misreporting his studies of children on low-cholesterol diets illustrates the biomedical community’s increasing concern about scientific misconduct, according to NIH Deputy Director William Raub.

Glueck, who has received several NIH grants, was formally censured by the agency last month. It has recommended that Glueck be barred from receiving any federal funds for two years, and banned from serving on any government advisory group for five years.

The NIH report concludes an unusually speedy disciplinary process that began in July 1986. At that time, the agency asked the University of Cincinnati, where Glueck was a professor of internal medicine, to investigate allegations about a Glueck paper scheduled for publication in Pediatrics.

The paper concluded that a low-cholesterol diet, at times supplemented with drugs, effectively lowered high blood cholesterol levels in children but did not interfere with their growth and development. Scientists familiar with ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies